Successful Rechallenge with Imatinib in a Patient with Chronic Myeloid Leukemia Who Previously Experienced Imatinib Mesylate Induced Pneumonitis

Imatinib mesylate is a targeted therapy that acts by inhibiting tyrosine kinase of the bcr-abl fusion oncoprotein, which is specific to chronic myeloid leukemia (CML), and the c-transmembrane receptor, which is specific to gastrointestinal stromal tumors. Interstitial pneumonitis is a rare adverse e...

Descripción completa

Detalles Bibliográficos
Autores principales: Go, Seong Woo, Kim, Boo Kyeong, Lee, Sung Hak, Kim, Tae-Jung, Huh, Joo Yeon, Lee, Jong Min, Hah, Jick Hwan, Kim, Dong Whi, Cho, Min Jung, Kim, Tae Wan, Kang, Ji Young
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Academy of Tuberculosis and Respiratory Diseases 2013
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3884114/
https://www.ncbi.nlm.nih.gov/pubmed/24416057
http://dx.doi.org/10.4046/trd.2013.75.6.256

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3884114/
https://www.ncbi.nlm.nih.gov/pubmed/24416057
http://dx.doi.org/10.4046/trd.2013.75.6.256

Ejemplares similares